Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
“We are introducing the complete range of Brivaracetam in India at a competitive pricing which will improve patient access. This product reaffirms our commitment towards improving epilepsy care by bringing multiple treatment options to patients and health care professionals in India,”
Chief Executive Officer – India Business Kirti Ganorkar said in a statement.
Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy.
While epilepsy is a common neurological disorder, because of the social stigma surrounding the disease, cultural practices and poor awareness of new treatment options, its management continues to be a challenge, the drug major said.
It is estimated that around 5.7 million to 6.4 million people in India suffer from epilepsy, it added.